TriangleNCT02299089 · OUTCOME
To Assess the Symptoms of Carcinoid Syndrome (Number of Bowel Movements and Flushing) and the Use of Rescue Medication Versus Baseline (by Using Patient Diaries) (NET)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- participants
- Interval / dispersion
- Not reported
- Time frame
- Baseline (Day 0), Day 84
What was measured
Number of bowel movements and flushing during period 0 and 1, data is presented as patients experience symptoms Bowel movement without flushing Bowel movement and flushing No Bowel movement or Flushing
Analysis population: Pharmacokinetic population
Groups in this outcome
CAM2029 10 mg q2w (NET)
CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks octreotide FluidCrystal® injection depot
CAM2029 20 mg q4w (NET)
CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly octreotide FluidCrystal® injection depot
| Group | Source count |
|---|---|
| CAM2029 10 mg q2w (NET) | 1 |
| CAM2029 20 mg q4w (NET) | 4 |
Reported measurements
Bowel movements without flushing
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| CAM2029 10 mg q2w (NET) | 1 | Not reported | Not reported | Not reported | Not reported |
| CAM2029 20 mg q4w (NET) | 0 | Not reported | Not reported | Not reported | Not reported |
Bowel movements with flushing
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| CAM2029 10 mg q2w (NET) | 0 | Not reported | Not reported | Not reported | Not reported |
| CAM2029 20 mg q4w (NET) | 2 | Not reported | Not reported | Not reported | Not reported |
No Bowel movement or Flushing
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| CAM2029 10 mg q2w (NET) | 0 | Not reported | Not reported | Not reported | Not reported |
| CAM2029 20 mg q4w (NET) | 2 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 0
- title
- Bowel movements without flushing
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 2
- title
- Bowel movements with flushing
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 2
- title
- No Bowel movement or Flushing
- denoms
- counts
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 4
- units
- Participants
- description
- Number of bowel movements and flushing during period 0 and 1, data is presented as patients experience symptoms Bowel movement without flushing Bowel movement and flushing No Bowel movement or Flushing
- groups
- description
- CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks octreotide FluidCrystal® injection depot
- id
- OG000
- title
- CAM2029 10 mg q2w (NET)
- description
- CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly octreotide FluidCrystal® injection depot
- id
- OG001
- title
- CAM2029 20 mg q4w (NET)
- param Type
- NUMBER
- population Description
- Pharmacokinetic population
- reporting Status
- POSTED
- time Frame
- Baseline (Day 0), Day 84
- title
- To Assess the Symptoms of Carcinoid Syndrome (Number of Bowel Movements and Flushing) and the Use of Rescue Medication Versus Baseline (by Using Patient Diaries) (NET)
- type
- OTHER_PRE_SPECIFIED
- unit Of Measure
- participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice